Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE-lung
2024-512288-29-00Phase 2Authorised
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of amivantamab, lazertinib and bevacizumab-bvzr in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Objective response rate at 12 weeks (RECIST v1.1). Planned start Apr 2023; status: authorised.
02
Drugs
amivantamablazertinibbevacizumab-bvzr
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512288-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512288-29-00.